Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.

Our cell therapy program uses stromal cells engineered to express a cell adhesion molecule called E-selectin. We call these “supercharged” stromal cells because in animal models they promote exceptional tissue repair. For our gene therapy program, we simplify the approach by using established gene therapy vectors to give injured tissues the E-selectin molecule directly..

RORA Bio is developing a first-in-class T-cell platform for targeting indications across cancer and infectious diseases. The platform consists of a newly discovered, long-lived, stem-like memory cell population that we call “RORA-Tscm”. Since presence of RORA-Tscm cells correlates with reduced tumor burdens in animal models and is emerging as a hallmark of better clinical outcomes for some patients, we are developing these cells in two formats: 1) modified with a mono- or bispecific chimeric receptor antigen (CAR) to make new CAR-T drugs with potential to be more durable, safer and long-lasting, and 2) as a stand-alone therapy to reconstitute the immune system of HIV infected patients.

Regenesance BV (now Complement Pharma BV) is a biotech company focusing on complement inhibition to modify neurodegenerative disease progression. The Company was founded to translate the opportunities of complement (C6) inhibition into clinical products for patients.

RSF Bio is a clinical stage cardiovascular therapeutics platform company based in San Diego, California. The company is developing Ataciguat: a small molecule drug developed to slow the progression of  Calcific Aortic Valve Stenosis (CAVS) to delay surgical valve replacement in patients.

Orbit Genomics is a cancer diagnostic company developing its proprietary Orbiseq™ platform for early detection, treatment and prevention of complext diseases. The platform analyzes repetitive DNA, which uniquely reflects both inherited and acquired disease risk. The first target is early detection of lung cancer, which is the leading cause of cancer death for both men and women in the US.

LiliumX uses protein building blocks to construct complex bispecific and multispecific biologics
Our modular approach lets us freely design drug candidates with custom modifications to create first-in-class therapeutics.

Cenexum Technologies is developing the next generation of neural interfacing technology enabling wireless powered bi-directional communication with the nerve tissue for patients without sufficient therapeutic treatment today.